Abstract
• This Express Update has been issued in response to the approval of rucaparib and MIRV. • It includes rucaparib as a first-line PARPi maintenance option in EOC. • MIRV is recommended for recurrent, high FRα ovarian cancer after 1-3 prior therapies and platinum-free interval of <6 months. • Updated treatment algorithms support personalised therapy in newly diagnosed and recurrent EOC.